GSK mulling Pfizer consumer business acquisition

Jan 09, 2018

GlaxoSmithKline’s chief executive Emma Walmsley recently announced that the drugmaker is looking at Pfizer’s consumer products business. But Walmsley stated that while it is considering the acquisition, GSK would not overpay for the asset.

Walmsley, who was formerly the head of GSK's consumer healthcare division, said that the company’s pharmaceuticals business and pharma research and development is still its top priority. Still, Walmsley believes that GSK's consumer business has room to grow and that the British drugmaker has traditionally been competent in integrating large acquisitions.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments